FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
AssigneeMerck Sharp & Dohme Corp.
InventorsJoel M. Harris, Bernard R. Neustadt, Andrew W. Stampford
Life of this patent
Estimating the term…
Abstract
The present invention relates to certain fused tricyclic heteroaryl rings compounds of the Formula (I) (also referred to herein as the “Fused Tricyclic Compounds”), wherein M, Q, U, W, X, Y, Z, R1, R2, and R3, and rings C and D are as herein described. The present invention also provides compositions comprising at least one Fused Tricyclic Compound, and use of such compounds in the treatment of central nervous system diseases or disorders such as Parkinson's disease.
Claims14
-8. (canceled)
The following compounds or a pharmaceutically acceptable salt thereof:
A compound of Formula (IB)
- wherein
- M is a direct bond, C═O, —CH2—, or —CH(OH);
- R1 and R3 are independently selected from H or halo;
- R2 is H;
- and
- R5, R6, and R7 are independently selected from H or halo;
- or a pharmaceutically acceptable salt thereof.
-14. (canceled)
A compound of Formula (IC):
- wherein
- M is —CH2—;
- R1 and R3 are independently H or halo;
- R2 is H;
- and
- R5, R6, and R7 are independently H or halo;
- or a pharmaceutically acceptable salt thereof.
-20. (canceled)
A compound of Formula (ID):
- wherein
- M is —CH2—;
- R1 and R3 are independently H or halo;
- R2 is H;
- and
- R5, R6, and R7 are independently H or halo;
- or a pharmaceutically acceptable salt thereof.
-26. (canceled)
Dependencies are inferred from the claim text.